Global Mycoplasma Testing Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024
The Global Mycoplasma Testing Market was valued at USD 606.9 million in 2017, and is expected to reach USD 1358.2 million by 2024, at a augmenting CAGR of 12.3% during 2018-2024.
The growth can be primarily attributed to the increasing incidence of mycoplasma contamination, and increasing research and development activities in the field of life sciences. In addition, increasing capital investment in the field of life sciences coupled with stringent regulatory norms to reduce contamination is also projected to drive the market during the forecast period.
The years used for the assessment are as follows;
Historical year: 2014, 2015, and 2016
Base year: 2017
Forecast period: 2018 – 2024
The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;
Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
Interacting with key opinion leaders of the market and developing data points based on interaction with them
Study of past trends in the market and their year on year Impact on the market size and share
Analyzing the collected data points
Bridging the data points to calculate the total mycoplasma testing market and its various segments
Anticipating potential risks
Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global mycoplasma testing market
Finalizing the overall size and share of the global mycoplasma testing market
To analyze market trends, opportunities, drivers, and restraints associated with the global mycoplasma testing market
To study market response with respect to the mergers and acquisitions in the industry
To profile key companies operating in the mycoplasma testing market and provide their competitive landscape
The research scope for mycoplasma testing market is as follows:
By Product Type
Kits & Reagents
Elimination Kits & Reagent
Standards & Controls
Nucleic Acid Detection
ELISA (Enzyme-linked Immunosorbent Assay)
Microbial Culture Techniques
PCR (Polymerase Chain Reaction)
Cell Line Testing
End of Production Cells Testing
Academic Research Institutions and Organizations
Pharmaceutical & Biotechnology Companies
Contract Service Laboratories
Rest of the World (RoW)
The demand for mycoplasma testing in biopharmaceutical sector is on the rise as mycoplasma contaminates the cell culture and affects the entire production batch. The bacteria grow in cell culture media and can reach very high numbers without causing visible changes in the culture while affecting cell cultures (changes in metabolism, biochemical or immunologic properties, growth, and viability). The mycoplasma testing offers revolutionary opportunities for pharmaceutical and biotechnology companies. To minimize the financial risk and maintain product quality, manufactures collect thousands of samples for sterility and bioburden testing every year. With Increasing research and development activities and growing demand for biopharmaceutical products, regulatory bodies such as FDA and EMA are expected to increasingly approve mycoplasma testing for biopharmaceutical products in coming years.
The factors which are driving the growth of the market are the increasing incidence of mycoplasma contamination, and increasing research and development activities in the field of life sciences. In addition, increasing capital investment in the field of life sciences coupled with stringent regulatory norms to reduce contamination is also projected to drive the market during the forecast period.
Geographically, North America held the largest share of the market in 2017. The growth in the region is attributed to the increasing research and development activities in the biopharmaceutical industries and availability of the various types of kit and reagents. Moreover, continued research and development on new assays and kits, and growing demand from end-user industries such as pharmaceutical & biotechnology, cell banks, and contract service laboratories is further boosting the market growth in the region. Europe held the second largest share of the global mycoplasma testing market in 2017. Asia-Pacific is expected to grow at the highest CAGR during 2018-2024. The growth of mycoplasma testing market in Asia-Pacific region is attributed to growing pharmaceutical and biotechnological industry and strong demand for mycoplasma testing from these sectors. Moreover, technological advancements in mycoplasma testing methods and increasing investment in R&D activities are further propelling the market growth in the region.
Some of the key companies operating in the market include Roche Diagnostics, Lonza Group Ltd, Merck KGaA, PromoCell GmbH, InvivoGen, Charles River Laboratories, Inc., SGS SA, American Type Culture Collection, Bionique Testing Laboratories, Inc., Biological Industries Israel Beit Haemek Ltd, and among others.